In this community, professionals share information regarding the clinical, programmatic and community-oriented aspects of early diagnosis, treatment and prevention of multi-drug-resistant tuberculosis (MDR-TB). Members also use this forum to promote universal access to quality care for MDR-TB.
World Health Organization - WHO
Brigham and Women's Hospital, Division of Global Health Equity
This Expert Panel explores the risk of QT prolongation in emerging drug-resistant tuberculosis (DR-TB) therapy.
The World Health Organization is developing guidance on the use of LAM and TB-LAMP. Join experts in discussing these new diagnostics for TB and share your input with the community.
We’re excited to announce that we’ll be hosting an Expert Panel on new rapid molecular techniques and TB transmission risk reduction on our TB-IC community July 13 – 17. We have great panelists who will discuss field implementation issues of new diagnostic…
Annex 2. Minimum laboratory requirements for introduction of bedaquiline Laboratory requirements Smear (ZN and/or FM) Rapid molecular tests (Xpert® and/or LPA) Culture (solid and/or liquid) Diagnosis of MDR-TB (at least RR-TB) EQA system in place Access to…
BEDAQUILINE DONATION REQUIREMENTS: http://www.stoptb.org/assets/documents/gdf/drugsupply/Bedaquiline%20Donation%20%20Annex%201%20and%20SAE-ADR%20Form.doc
Fulbright U.S. Student Program
I focus more in the quantitative research for a healthcare team at an applied think tank that focuses on emerging markets. My main work has been in mathematical modeling of disease transmission (for TB and malaria), but I also work on system dynamics for health technologies/products such as the DMPA contraceptive.
University of Michigan; William Davidson Institute